CompletedNCT03647215
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Biosciences UK
- Principal Investigator
- Michael Thompson, MDIncyte Biosciences UK
- Enrollment
- 427 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2021
Study locations (30)
- Limerick University Hospital, Limerick, Dooradoyle, Ireland
- University Hospital Waterford, Waterford, Ireland
- Royal Cornwall Hospital, Truro, Cornwall, United Kingdom
- Royal Devon & Exeter Hospital, Exeter, Devon, United Kingdom
- Derriford Hospital, Plymouth, Devon, United Kingdom
- Broomfield Hospital Chelmsford, Chelmsford, Essex, United Kingdom
- Queen's Hospital, Romford, Essex, United Kingdom
- Aberdeen Royal Infirmary, Aberdeen, Foresterhill, United Kingdom
- Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom
- Medway Maritime Hospital, Gillingham, Kent, United Kingdom
- Blackpool Victoria Hospital, Blackpool, Lancashire, United Kingdom
- Royal Oldham Hospital, Manchester, Lancashire, United Kingdom
- Queens Medical Centre, Nottingham, Nottinghamshire, United Kingdom
- Ipswich Hospital, Ipswich, Suffolk, United Kingdom
- Heart of England NHS Foundation Trust, Birmingham, West Midlands, United Kingdom
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03647215 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics